Artificial Intelligence
Biopharmaceuticals Contract Manufacturing market is projected to grow at a CAGR of 10.0% by 2033: Visiongain
As per the report by Visiongain, the Biopharmaceuticals Contract Manufacturing Market was valued US$14,140.0 million in 2022 and is projected to grow at a CAGR of 10.0% during the forecast period 2023-2033.
Visiongain has published a new report entitled Biopharmaceuticals Contract Manufacturing 2023-2033. Forecasts by Source (Mammalian, Non-mammalian), by Service (Process Development, Fill & Finish Operations, Analytical & QC Studies, Packaging), by Product (Biologics, Biosimilars), by Company Size (Small, Mid-sized, Large), by Scale of Operations (Preclinical, Clinical, Commercial) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis
CROs offer a unique value to biotech businesses, which tend to grow quickly and be resourceful. Established pharma companies can build best-in-class capabilities in-house and selectively outsource, but biotech companies often have to rely on others to provide the full range of clinical services before they can think about building their own development organisations. This is because biotech companies grow quickly and don’t have as much infrastructure for development.
Also, biotech companies often haven’t made a name for themselves yet. When it comes to interacting with clinical-trial sites, investigators, patients, caregivers, and regulators around the world, biotech companies may not have the same connections or name recognition as a large biopharma or global CRO that has people on the ground and relationships with stakeholders in many countries.
Also, innovation in clinical development today often means working with specialised companies that offer best-in-breed point solutions, such as electronic clinical outcome assessments, trial payments, and decentralised or virtual trials. Several players such as Science37 and Documentum, focus on one or more parts of the clinical trial life cycle. This is in addition to big companies like Oracle and Veeva that offer technology and data-enablement services for all development activities. Contracting with several best-in-class vendors separately may result in the most advanced clinical trials, but it also takes large-scale vendor management skills and processes that most new biotech companies can’t handle on their own.
So, biotech companies may partner with a bigger company, like BioNTech did with Pfizer and Genmab did with Janssen and AbbVie, or they may turn to a CRO, which can act as both a general contractor for outside services and a source of practical innovation. CROs that know where biotech companies feel underserved and align their services to fill in the gaps should find a lot of chances to help this fast-growing sector.
Download Exclusive Sample of Report
How has COVID-19 had a Significant Impact on the Biopharmaceuticals Contract Manufacturing Market?
Due to the challenges caused by COVID-19, many businesses have had to hire new contract manufacturers or suppliers of ingredients to keep up with rising demand. Also, because the biopharmaceutical business is always growing, companies that do their own manufacturing are having trouble with production problems like a lack of expertise and high-tech equipment. The number of early-stage bio/pharma businesses has grown because biotechnology is getting better and there are more ways to get money from outside sources.
Investors’ interest in biopharmaceuticals has expanded to include services such as contract development and manufacturing organisations (CDMOs) and commercial research organisations (CROs). Ampersand Capital, for example, bought Vibalogics, a CDMO that specialises in viridae, live bacteria, and aseptic processing, and Permira bought Quotient Sciences, a UK-based early-stage drug research firm. However, when finances and resources are shifted to “COVID medicines” at the cost of other biologics projects under development for other therapeutic areas, the pandemic has had some detrimental knock-on consequences. Inquiries and orders for pandemic vaccines and medicines are increasing, according to service providers, CDMOs and CROs.
How will this Report Benefit you?
Visiongain’s 360-page report provides 140 tables and 167 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the biopharmaceuticals contract manufacturing market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Biopharmaceuticals Contract Manufacturing. Get financial analysis of the overall market and different segments including source, service, product, company size, scale of operations and capture higher market share. We believe that there are strong opportunities in this fast-growing biopharmaceuticals contract manufacturing market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
What are the Current Market Drivers?
Technological Breakthroughs Driving Industry Growth
Several technological breakthroughs in the last few decades have had a big effect on how small-molecule drugs are made. Also, with the rise of new technologies, biologics have had a big effect on the pharmaceutical industry, bringing about new ways to treat a wide range of diseases, including immune, oncological, and rare ones. Also, the positive results of ongoing clinical research projects have led the government and private sector to spend a lot of money in this field. For example, in 2021, more than US$70 billion was put into the field of cell and gene therapy. But making biologics is not easy and has many problems. Some of the main things that worry innovators today are the rate of drugs or therapies falling out of the pipeline, long development times, the limitations of the facilities they have now, problems with regulations and compliance, and inconsistencies in the quality of the end product. So, people who make therapies are constantly looking for ways to get around the problems that already exist. Outsourcing has become a profitable choice for people who make biologic drugs, among other things.
At the moment, a lot of companies in the biopharmaceutical field prefer to transfer different tasks to contract service providers, such as biologics manufacturing. Also, it’s important to note that biopharmaceutical contract manufacturers are working hard to strengthen their positions in this field by forming strategic partnerships. This is so they can keep up with the growing demand for biologics. For this reason, there have been large growth, mergers, and acquisitions in this market, as service providers try to become one-stop shops that can meet all of their customers’ needs. Since outsourcing is becoming more and more accepted as a good way to run a business in this area, we expect the biopharmaceutical contract manufacturing market (biopharma CDMO/biopharma CMO) to grow at a significant growth rate in the next few years.
Quick Turnaround Time Offered by CMOs Projected to Boost Industry Growth
Bioprocessing improvements and breakthroughs have been very important to the growth of contract service providers because they have helped them solve problems like high production costs and the need to change over between batches. One of the most important innovations is the use of bioprocessing systems that only need to be used once. This helps lower the costs of production and scaling up. Also, CMOs have grown a lot because single-use goods have a quick turnaround time and don’t require a lot of extra work, such as changeover and cleaning validation.
One common trend in the industry is mergers, acquisitions, and joint ventures, which help CMOs give integrated bioprocessing services to their clients and, in turn, make them a more reliable choice for a quick product launch for commercial use. Large companies, on the other hand, think that outsourcing is risky because they lose strategic control and have less management oversight. Because of this, big pharmaceutical businesses choose to keep their manufacturing in-house. This is likely to slow down the growth of CMOs to some degree.
Download Exclusive Sample of Report
Where are the Market Opportunities?
Expansion of Fill-and-Finish CMOs
CMOs have provided biopharmaceutical companies with a vast array of services, from cell culture to product packaging. CMOs provide manufacturing services including process development, fill and finish, analytical and quality control research, and packaging. Due to rising quality concerns and regulatory changes in biopharmaceutical development, the category of analytical & QC studies is anticipated to grow at a significant rate over the forecast period. In accordance with regulatory requirements, new constraints are being imposed on CMOs producing biologics to ensure product purity and safety.
Emerging Economies to Offer Lucrative Growth Opportunities
In terms of API production, Asia-Pacific is a sizable region with numerous expanding nations. Despite the fact that the APAC region has a smaller share of healthcare expenditures than established markets in North America and Europe, the region’s growth rate has surpassed that of established markets in North America and Europe. As a result of rising healthcare expenditures, healthcare in APAC has become more affordable and pharmaceutical product demand has increased. The majority of medications used in the United States are produced in domestic facilities. Pharmaceutical companies that sell their products in North America and Europe also rely heavily on contract manufacturers as outsourcing partners. As a result of increased competition, price constraints, and regulatory changes, pharmaceutical companies are outsourcing the procurement and production of raw materials. Asia-Pacific is the fastest-growing market for APIs due to rising consumption, expenditures on healthcare, and availability of pharmaceuticals.
Competitive Landscape
The major players operating in the biopharmaceuticals contract manufacturing market are AbbVie, Inc., AGC Biologics, Avantor, Inc., Binex Co., Ltd., Boehringer Ingelheim GmbH, Cambrex Corporation, Catalent Inc, Curia Global, Inc., Cytiva, FUJIFILM Diosynth Biotechnologies, JRS PHARMA, Jubilant Pharma Limited, KBI Biopharma, Lonza, Pfizer CentreOne, ProBioGen, Rentschler Biopharma SE, Samsung Biologics, Sandoz, TOYOBO CO., LTD., Thermo Fisher Scientific and WuXi Biologics among others. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.
Recent Developments
- In March 2023, Catalent launched ProteoSuiteSM Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into clinical trials. These emerging therapeutic modalities are typically highly potent and present novel oral bioavailability challenges to formulators.
- In November 2022, FUJIFILM Diosynth Biotechnologies expanded its strategic partnership with North Carolina State University (NC State) to create future innovation opportunities through new research projects, sustainable facility design, and bioprocessing advancements at the future Holly Springs cell culture biomanufacturing site. The strategic partnership will focus areas of research and facility design to support FUJIFILM Diosynth Biotechnologies’ goal to achieve net-zero carbon emissions by 2030 for its new $2 billion site in Holly Springs. Additionally, the strategic partnership will create opportunities for the organizations to develop new bioprocess development techniques using machine learning, artificial intelligence, and analytical methods.
To access the data contained in this document please email [email protected]
To find more Visiongain research reports on the Pharma sector, click on the following links:
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: [email protected]
About Visiongain
Visiongain is one of the fastest-growing and most innovative independent market intelligence providers around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with a lot of synergies. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customised and syndicated market research reports offer a bespoke piece of market intelligence customised to your very own business needs.
Contact:
Visiongain Reports Limited
Telephone: +44 (0) 20 7336 6100
Email: [email protected]
Web: www.visiongain.com
Artificial Intelligence
How AIoT shapes the future of mobility: Hikvision at ITS World Congress 2024
HANGZHOU, China, Sept. 27, 2024 /PRNewswire/ — Hikvision made a significant impact at the ITS World Congress in Dubai with its captivating theme, “Embrace AIoT for safer, smarter, and greener mobility.” Its booth became a hub of innovation, where visitors explored AIoT solutions that are reshaping the transportation landscape, sparking deep conversations on the future of urban mobility.
Road safety revolution: harnessing AIoT for secure transportation
Hikvision’s commitment to road safety was on full display at its booth through the impressive array of AIoT solutions designed to create secure and reliable traffic environments. The company’s technology provides 24/7 traffic monitoring, ensuring continuous oversight of motor vehicles, non-motorized vehicles, pedestrians and environmental factors. This comprehensive, real-time information collection enables traffic managers to prevent accidents and enhance road safety. Among the showcased products was the 20 MP IR ANPR Checkpoint Capture Unit, renowned for its high-definition capture capabilities, bolstering traffic safety measures.
A standout innovation was the integration of advanced radar and camera technologies, ensuring uninterrupted, comprehensive detection even in adverse weather conditions. The Radar-Video Fusion Incident Detection Cameras, featured prominently in the product experience area, enable early detection and warning of potential hazards. They are particularly effective in challenging situations such as curved roads, blind spots at intersections, and obstacles beyond visual range.
Attendees also engaged with onboard monitoring products on the simulated bus, including dome network cameras, which is designed to enhance passenger safety. Driving assistance products, such as the Driver Status Monitor (DSM), were demonstrated to mitigate unsafe driving behaviors and ensure safer journeys.
Urban mobility redefined: smart traffic innovations
In the realm of smarter mobility, Hikvision showcased its multidimensional sensing technology, which integrates visible light sensors, infrared sensors, radar, and sonar. This technology expands perception capabilities, significantly improving traffic management and situational awareness. The use of AI-powered comprehensive sensing elevates incident monitoring and violation detection to unprecedented levels of accuracy and efficiency.
A major attraction was the Radar-Video Fusion TandemVu PTZ Camera, which integrates millimeter-wave radar with high-resolution cameras for extensive traffic detection and data analysis. AI-based algorithms combine these two systems to enhance target information, detecting up to 16 types of incidents. This leads to the development of a large-scale fusion model that merges spatial physical data with image semantic information. The result is ultra-long-range perception, achieving over 95% accuracy in vehicle trajectory detection. This robust system improves traffic violation management and optimizes traffic flow, significantly enhancing road efficiency.
At the simulated bus station, visitors observed how AI-assisted people counting automated the collection of passenger flow statistics at peak stop hours and bus line frequency during busy periods. Paired with smart bus stop digital signage, the solution improves bus service quality, operational efficiency, passenger experience, and overall public transport effectiveness.
Sustainable transportation: leading the charge for greener cities
Hikvision’s commitment to sustainable urban mobility was evident through its innovative green wave technology and eco-friendly checkpoint solutions. Green wave technology efficiently manages traffic flow to reduce congestion and lower carbon emissions, aligning with global sustainability goals. Visitors were particularly impressed by a case study showcasing a green wave solution implemented in Zhoushan, China. Over a stretch of 21 kilometers and 34 intersections, this main road cut travel times by 50%.
The use of DarkFighterX technology in checkpoint cameras also received significant attention. This technology senses both visible and invisible light, resulting in more accurate and realistic images. It enhances traffic violation enforcement efficiency while minimizing the need for high ambient light levels, thus reducing light pollution. The 9M DarkfightX ANPR Checkpoint Camera exemplified this dedication to environmental stewardship.
Frank Zhang, President of Hikvision MEA, remarked, “Hikvision supports sustainable urban planning by empowering traffic departments to address congestion and transportation challenges.” He further emphasized, “Our system’s openness fosters a secure and reliable platform for developing smart and green cities. Additionally, our solar technology is extensively utilized in remote areas, while our smart street lighting solutions reduce energy consumption by 20-30%, promoting intelligent urban transportation and advancing global sustainability objectives.”
Hikvision’s presence at the ITS World Congress in Dubai underscored its leadership in integrating AIoT technologies to drive safer, smarter, and greener mobility solutions. The engaging presentations and advanced product demonstrations captured significant attention from industry partners and customers, reaffirming the company’s role as a pioneer in shaping the future of urban transportation. As the world moves towards more intelligent and sustainable transportation systems, Hikvision remains at the forefront, embracing AIoT to create a safer, smarter, and greener future for all.
To find out more about Hikvision’s advanced traffic and public transport solutions, please explore the Hikvision official website.
Photo – https://mma.prnewswire.com/media/2516934/How_AIoT_shapes_future_mobility_Hikvision_ITS_World_Congress_2024.jpg
View original content:https://www.prnewswire.co.uk/news-releases/how-aiot-shapes-the-future-of-mobility-hikvision-at-its-world-congress-2024-302261298.html
Artificial Intelligence
Anti-Drone Market worth $7.05 billion by 2029 – Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., Sept. 27, 2024 /PRNewswire/ — The global anti-drone market was valued at USD 2.16 billion in 2024 and is projected to reach USD 7.05 billion by 2029; it is expected to register a CAGR of 26.7% during the forecast period according to a new report by MarketsandMarkets™. Increasing government spending on counter-drone technologies, rising incidence of critical infrastructure security breaches by unauthorized drones, and surge in adoption of aerial remote sensing technologies to safeguard critical infrastructure are attributed to the demand for anti-drone.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=177013645
Browse in-depth TOC on “Anti-Drone Market” 178 – Tables61 – Figures253 – Pages
Anti-Drone Market Report Scope:
Report Coverage
Details
Market Revenue in 2024
$ 2.16 billion
Estimated Value by 2029
$ 7.05 billion
Growth Rate
Poised to grow at a CAGR of 26.7%
Market Size Available for
2020–2029
Forecast Period
2024–2029
Forecast Units
Value (USD Million/Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
By System Type, Application, Platform type, Vertical, and Region
Geographies Covered
North America, Europe, Asia Pacific, and Rest of World
Key Market Challenge
Vulnerability to hacking
Key Market Opportunities
Emphasis on improving unmanned aircraft systems technology
Key Market Drivers
Growing number of illicit activities
By System Type: Hybrid systems to account for the larger market share in the forecasted year.
The hybrid segment accounted for the largest share of the anti-drone market in 2029. The trends of integrating multiple anti-drone technologies are rising since they are most effective in detecting, tracking, and neutralizing drone threats. These systems merge electronic, kinetic, and lasers, providing a comprehensive defense solution against UAVs. Hybrid systems use electronic, kinetic, and laser-based countermeasures to offer optimum protection against drones. These systems are designed to detect, track, identify, categorize, and mitigate drones at operational wide ranges ranging from a few km up to tens of km.
By Platform: The ground-based segment accounted for the largest market share in the forecast year.
The ground-based segment will hold a major share of the anti-drone market in 2029. Many ground-based anti-drone systems use several electronic technologies, such as radar, IR sensors, acoustic systems, and RF & GNSS jammers. MESA radar solutions are used mostly for counter-UAS purposes, protecting critical infrastructure, military camps, and other security-sensitive sites from unauthorized drones. One such solution is EchoGuard, a ground-based airspace management solution that contains a software-defined 3D radar that can be specific to the site. This system can identify single or multiple off-chance drones, including swarms in unauthorized areas. They provide accurate and sustained airspace surveillance for the field of view (FOV) they are configured, and both human and AI-monitored visual checks. The system can be easily transported and integrated directly with the command-and-control centers or another identification sensor for portable use, and multiple units of the system can be combined to cover vast areas or lengths of borders. Major providers of ground-based counter-drone systems include companies like EchoDyne Corporation, DeTect, Meteksan Defense, and WhiteFox Defense. Acoustics-based Discovair G2 utilizes patented microphone arrays. With 128 interconnected microphone elements, the Discovair sensor units can establish azimuth and elevation to the target in real-time using advanced digital signal processing.
Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=177013645
By Region: Americas are expected to hold the largest share of the anti-drone market during the forecast period.
Americas is expected to capture the largest share in the anti-drone industry during the forecast period. The growth can be attributed to protecting crucial infrastructure in the region. Governments, particularly in the US, invest in anti-drone systems for military bases, borders, and critical infrastructure. For Instance, in April 2023, RTX secured a USD 237 million contract from the US Army to provide Ku-band Radio Frequency Sensors (KuRFS) and Coyote effectors. These systems are designed to detect and neutralize unmanned aircraft systems (UAS). The contract includes stationary and mobile systems and a specified quantity of effectors, all aimed at enhancing the Army’s operations within the US Central Command region.
Key Players-
The key companies offering anti-drone companies include RTX (US), Lockheed Martin Corporation (US), Leonardo S.p.A. (Italy), Thales (France), and IAI (Israel).
Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=177013645
Browse Adjacent Market: Semiconductor and Electronics Market Research Reports &Consulting
Related Reports:
Drone Sensor Market Size, Share, Industry Growth & Trends by Sensor Type, Platform (VTOL Type, Fixed Wing Type, Hybrid Type), Application (Navigation, Collision Detection & Avoidance, Data Acquisition, Motion Detection, Power Monitoring), End Users and Region – Global Forecast to 2029
Smart Agriculture Market Size, Share, Statistics and Industry Growth Analysis Report by Offering (Hardware, Software, Services), Agriculture Type, Farm Size (Large, Medium, Small), Application (Precision Farming, Livestock Monitoring) and Region (America, Europe, Asia Pacific, Row) – Global Forecast to 2028
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact: Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected] Our Web Site: https://www.marketsandmarkets.com/Research Insight: https://www.marketsandmarkets.com/ResearchInsight/anti-drone-market.aspContent Source: https://www.marketsandmarkets.com/PressReleases/anti-drone.asp
Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg
View original content:https://www.prnewswire.co.uk/news-releases/anti-drone-market-worth-7-05-billion-by-2029—exclusive-report-by-marketsandmarkets-302260893.html
Artificial Intelligence
CluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize Clinical Data Review
CluePoints furthers its commitment to delivering innovative solutions that enhance clinical trial efficiency with this latest addition to its enterprise software platform.
KING OF PRUSSIA, Pa., Sept. 27, 2024 /PRNewswire/ — CluePoints continues to transform clinical trial review and leverage its industry-leading software to enhance the interrogation, analysis and presentation of data with the launch of its latest application, Medical & Safety Review (MSR).
The tool simplifies and streamlines the medical analysis of study data through user-friendly dashboards, data manipulation and cleaning, query management and full transparency over the data history. This not only improves efficiency and communication in medical oversight, but also elevates patient safety, differentiating MSR as a smarter and unique solution.
Designed by, and for Medical and Safety Reviewers, MSR converts the manual analysis of patient outcomes, which can be prone to inefficiency and error, into an accurate, efficient process. MSR tackles time-consuming study preparation for specific visualizations by featuring a comprehensive standard visualization library as well as the ability to copy and reuse dashboards across different studies, enabling the identification of outlying values, change tracking, and improved communication for smarter clinical trials.
Other benefits of MSR include:
Enhanced medical review efficiency and reduced human errors via automated checksReduced time spent by clinical and data management teams in reviewing dataImproved collaboration with integrated review workflows across departmentsEnsured record quality and accountability with comprehensive change trackingDriving faster decision making with the proactive detection of trends and safety issuesEnsuring regulatory compliance with rule-based detection and user assignmentsAndy Cooper, Chief Executive Officer at CluePoints, commented, “We are thrilled to announce the launch of Medical & Safety Review to our growing product offerings. MSR is the latest application addition to the CluePoints platform, which includes products such as Risk-Based Quality Management (RBQM) and our Site Profile & Oversight Tool (SPOT). Together, they provide a comprehensive approach to clinical trial optimization, enhancing data integrity, ensuring regulatory compliance, and accelerating drug development. The creation of MSR ensures a more streamlined review process while prioritizing patient safety at every step and empowers medical teams to swiftly identify outliers, track data changes, and improve communication.”
To learn more about CluePoints’ award-winning solutions, please visit www.cluepoints.com
About CluePoints
CluePoints is the premier Risk-Based Quality Management (RBQM) and Data Quality Oversight Software provider. We are leveraging the potential of Artificial Intelligence using Advanced Statistics and Machine Learning to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R2), CluePoints is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation, you now have everything you need to adhere with global regulatory guidance. The result is positive clinical development outcomes, increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBQM.
View original content:https://www.prnewswire.co.uk/news-releases/cluepoints-launches-medical–safety-review-msr-software-to-revolutionize-clinical-data-review-302260936.html
-
Artificial Intelligence5 days agoEC-Council Unleashes AI-Powered Ethical Hackers on Cybercrime
-
Artificial Intelligence5 days agoHappiest Minds’ MD & CFO, Venkatraman Narayanan, recognized as the Leading CFO of the Year at the CII CFO Excellence Awards 2023-24
-
Artificial Intelligence5 days agoHospital in Greenland chooses Sectra’s radiology solution–enhanced cross-country collaboration for improved patient care
-
Artificial Intelligence5 days agoIBM and NASA Release Open-Source AI Model on Hugging Face for Weather and Climate Applications
-
Artificial Intelligence4 days agoSSCL partners with PolyAI to empower next-generation customer experience
-
Artificial Intelligence7 days ago
HUAWEI CONNECT 2024 | Huawei Unveils the Brand-New Xinghe Intelligent Fabric Solution, Powering the AI Era
-
Artificial Intelligence5 days agoBITBOT1000 Revolutionizes the Digital Market Landscape with AI-Driven Solutions
-
Artificial Intelligence5 days ago
Luminance Expands U.S. Footprint with New Dallas Office
